A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice
← catalyst calendarNCT03659669 · readout in 193 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Suspended
Study type
Observational
Enrollment
272estimated
Sites
13
Country
Israel
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Strategic considerations
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-02-10 | actual | When the study began enrolling |
| Primary completion | 2027-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2018-09-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2023-10-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Lymphocytic Leukemia (CLL)
Primary outcome
what the primary-completion date above is the date OFOverall Response Rate (ORR)
measured Up to approximately 12 months
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed